BC Extra | Sep 29, 2015
Politics & Policy

CMS proposes update to lab diagnostic reimbursements

CMS proposed an update to its Clinical Laboratory Fee Schedule (CLFS), under which laboratory-reported payments from private insurers would be used to calculate Medicare payments for clinical diagnostic tests. The new payment rates would be...
BC Week In Review | Jun 29, 2015
Clinical News

AlloMap Molecular Expression Test: Postmarketing study data

The observational, international CARGO II trial in 594 heart transplant patients showed that AlloMap scores of <34 points had a negative predictive value (NPV) of >=99% for moderate to severe acute cellular heart graft rejection....
BC Week In Review | Sep 1, 2014
Clinical News

AlloMap Molecular Expression Test: Clinical trial started

CareDx (formerly XDx) started the Donor-derived cell-free DNA Outcomes AlloMap Registry (D-OAR) to examine the utility of donor-derived cell-free DNA (dd-cfDNA) in a heart transplant recipient’s blood as a surveillance tool to monitor and diagnose...
BC Innovations | Jul 24, 2014
Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens Assessing circulating donor cell-free DNA levels to predict heart transplant rejection The ratio of circulating donor cell-free DNA to total cell-free DNA could be...
BC Extra | Jul 18, 2014
Financial News

CareDx raises $40 million in IPO

Molecular diagnostics company CareDx Inc. (NASDAQ:CDNA) raised $40 million through the sale of 4 million shares at $10 in an IPO. The price values the company at $115.7 million. Earlier this month, CareDx said it...
BC Extra | Jul 7, 2014
Financial News

CareDx, Pfenex set IPO terms

Molecular diagnostics company CareDx Inc. (Brisbane, Calif.) and biosimilar play Pfenex Inc. (San Diego, Calif.) both set IPO terms on Monday. CareDx (formerly XDX Inc.) plans to sell 3.1 million shares at $15-$17 in an...
BC Week In Review | Jun 2, 2014
Company News

CareDx, ImmuMetrix deal

Molecular diagnostics company CareDx (formerly XDx Inc.) will acquire transplant diagnostic company ImmuMetrix, which has R&D programs and IP in cell-free DNA. CareDx said the acquisition will strengthen its position in organ transplant surveillance. The...
BC Week In Review | Apr 7, 2014
Company News

XDx Inc sales and marketing update

XDx Inc. , Brisbane, Calif.   Business: Diagnostic   XDx said health insurer Cigna Corp. (NYSE:CI, Bloomfield, Conn.) issued a positive coverage decision for XDx's AlloMap Molecular Expression Test for patients from six months to five...
BC Week In Review | Jun 17, 2013
Company News

Diaxonhit, XDx Inc sales and marketing update

XDx and Diaxonhit entered into a memorandum of agreement to grant Diaxonhit exclusive rights to market and perform XDx's AlloMap Molecular Expression Test in Europe. XDx will receive an upfront payment upon signing of the...
BC Week In Review | Apr 22, 2013
Clinical News

AlloMap Molecular Expression Test: Clinical trial started

XDx began the Outcomes AlloMap Registry (OAR) to assess long-term clinical outcomes in about 2,000 heart transplant patients who are being managed with the AlloMap Molecular Expression Test as part of heart transplant rejection surveillance....
Items per page:
1 - 10 of 23